Display options
Cite
Liebson PR. Left Ventricular Hypertrophy. Curr Treat Options Cardiovasc Med. 1999;1(3):219-230doi: 10.1007/s11936-999-0038-0.
Liebson, P. R. (1999). Left Ventricular Hypertrophy. Current treatment options in cardiovascular medicine, 1(3), 219-230. https://doi.org/10.1007/s11936-999-0038-0
Liebson. "Left Ventricular Hypertrophy." Current treatment options in cardiovascular medicine vol. 1,3 (1999): 219-230. doi: https://doi.org/10.1007/s11936-999-0038-0
Liebson PR. Left Ventricular Hypertrophy. Curr Treat Options Cardiovasc Med. 1999 Oct;1(3):219-230. doi: 10.1007/s11936-999-0038-0. PMID: 11096487.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Cardiovasc Med. 1999 Oct;1(3):219-230. doi: 10.1007/s11936-999-0038-0.

Left Ventricular Hypertrophy.

Current treatment options in cardiovascular medicine

Liebson

Affiliations

  1. Section of Cardiology, Rush-Presbyterian-St. Luke's Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA.

PMID: 11096487 DOI: 10.1007/s11936-999-0038-0

Abstract

The presence of left ventricular hypertrophy (LVH) as a treatable entity is of particular importance in patients with primary hypertension. Because LVH is associated with a strong risk of adverse clinical events (eg, heart failure, ischemic events, and cardiovascular death) and because evidence from retrospective studies suggests that regression of LVH, along with a decrease in blood pressure, may help modify these outcomes, the use of antihypertensive agents that have been shown to promote regression of LVH has been recommended. These include diuretics, beta-blockers (except those with intrinsic sympathomimetic activity ), angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, peripheral alpha(1)-blockers, and central alpha(2)-stimulators. Agents to be avoided include direct arterial vasodilators (eg, hydralazine and minoxidil), which have strong sympathetic stimulating properties and tend to maintain LVH despite lowering blood pressure. The use of ACE inhibitors is increasing. Unfortunately, the cost of these agents is higher than that of some other classes of agents, such as diuretics, which show excellent evidence of regression of hypertrophy. African-American and elderly persons, in particular, may benefit from diuretics for treatment of hypertension as well as reduction of left ventricular (LV) mass. Beta-blockers should be considered in the elderly, especially those with greatly thickened LV walls and small chamber sizes, factors associated with hyperdynamic systolic performance, systolic midcavity obliteration, and diastolic relaxation abnormalities on echocardiography. Calcium channel blockers may also be useful in patients with LVH who have normal systolic performance and diastolic compliance abnormalities. The purpose of serial echocardiographic studies in patients already being treated for hypertension is to ensure that LV geometry has not worsened and that function is unchanged or improved (especially with respect to previously noted diastolic Doppler inflow abnormalities). Considerable changes in estimated LV mass (>60 g on serial intrapatient evaluation) are needed before the clinician can conclude with confidence that LV mass has decreased. More specific definitive recommendations based on the outcomes of current large-scale clinical trials are awaited.

References

  1. Hypertension. 1987 Feb;9(2 Pt 2):II69-76 - PubMed
  2. J Am Coll Cardiol. 1998 Jun;31(7):1635-40 - PubMed
  3. J Am Coll Cardiol. 1995 Feb;25(2):424-30 - PubMed
  4. J Hypertens. 1995 Oct;13(10 ):1091-5 - PubMed
  5. Circulation. 1997 Apr 15;95(8):2007-14 - PubMed
  6. Circulation. 1993 Oct;88(4 Pt 1):1893-906 - PubMed
  7. Am J Cardiol. 1997 Nov 15;80(10):1384-8 - PubMed
  8. Circulation. 1996 Jan 15;93(2):259-65 - PubMed
  9. J Am Coll Cardiol. 1995 Mar 15;25(4):879-84 - PubMed
  10. Am J Cardiol. 1987 Apr 15;59(9):956-60 - PubMed
  11. J Am Coll Cardiol. 1997 Dec;30(7):1802-8 - PubMed
  12. Am J Cardiol. 1996 Jul 15;78(2):197-202 - PubMed
  13. Am J Cardiol. 1991 May 1;67(11):1027-30 - PubMed
  14. Am J Med. 1989 Jul;87(1):22-7 - PubMed
  15. Am J Hypertens. 1997 Jul;10(7 Pt 1):705-13 - PubMed
  16. JAMA. 1996 May 15;275(19):1507-13 - PubMed
  17. J Am Coll Cardiol. 1986 Mar;7(3):639-50 - PubMed
  18. N Engl J Med. 1986 Feb 6;314(6):334-9 - PubMed
  19. Eur Heart J. 1993 Jul;14 Suppl D:22-32 - PubMed
  20. J Hypertens. 1995 Nov;13(11):1325-34 - PubMed
  21. Ann Intern Med. 1991 Mar 1;114(5):345-52 - PubMed
  22. Circulation. 1995 Feb 1;91(3):698-706 - PubMed
  23. JAMA. 1993 Aug 11;270(6):713-24 - PubMed
  24. Circulation. 1998 Nov 10;98 (19):2037-42 - PubMed
  25. Hypertension. 1996 Aug;28(2):269-75 - PubMed
  26. Am J Cardiol. 1996 Jul 15;78(2):203-7 - PubMed
  27. Circulation. 1994 Oct;90(4):1786-93 - PubMed
  28. Hypertension. 1996 May;27(5):1031-8 - PubMed
  29. Hypertension. 1997 Jan;29(1 Pt 2):519-24 - PubMed
  30. J Am Coll Cardiol. 1994 Apr;23 (5):1179-85 - PubMed
  31. Am J Hypertens. 1992 Feb;5(2):95-110 - PubMed
  32. Circulation. 1977 Apr;55(4):613-8 - PubMed
  33. Circulation. 1997 Aug 19;96(4):1330-6 - PubMed
  34. Am J Cardiol. 1996 Jul 1;78(1):61-5 - PubMed
  35. JAMA. 1998 Mar 11;279(10 ):778-80 - PubMed
  36. J Am Coll Cardiol. 1997 Mar 1;29(3):641-7 - PubMed
  37. Circulation. 1998 Nov 10;98(19):1987-9 - PubMed
  38. N Engl J Med. 1985 Jan 31;312(5):277-83 - PubMed

Publication Types